Johannes von Kempis - Concepedia

Author

Johannes von Kempis

Kantonsspital St. Gallen

Also Known As

Johannes Von Kempis, Johannes von Kempis, Matter, Christian, Michael Spaeth, Thomas Stoll

110

Publications

1.1K

Citations

H-Index

Concepts

All Affiliations

Kantonsspital St. Gallen Ludwig-Maximilians-Universität München University of Colorado Denver University of Freiburg Johannes Gutenberg University Mainz

About

Johannes von Kempis is an author at Kantonsspital St. Gallen specializing in medicine, immunology, and rheumatoid arthritis.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	6	6	208
2	Cell Biology	2	2	34
3	Public Health	1	1	45
4	Allergy	1	1	13
5	Epidemiology	1	1	45

Johannes von Kempis

Publications

678

Citations

H-Index

Page 1

	Year	Citations
Neuropeptide Y is an inducible gene in the human immune system Herbert Schwarz, Peter M. Villiger, Johannes von Kempis, Journal of Neuroimmunology Human Immune SystemMedicineImmunologyNeuropeptide YHypothalamic Peptide	1994	99
CD137 (ILA/4-1BB), expressed by primary human monocytes, induces monocyte activation and apoptosis of B lymphocytes Georg Kienzle, Johannes von Kempis International Immunology	2000	81
Vascular cell adhesion molecule 1 ?CD106) on primary human articular chondrocytes: Functional regulation of expression by cytokines and comparison with intercellular adhesion molecule 1 (CD54) and very late activation antigen2 Georg Kienzle, Johannes von Kempis Arthritis & Rheumatism	1998	56
Anti-SARS-CoV-2 mRNA vaccine in patients with rheumatoid arthritis Andrea Rubbert‐Roth, Nicolas Vuilleumier, Burkhard Ludewig, The Lancet Rheumatology	2021	51
Effectiveness, Tolerability, and Safety of Tofacitinib in Rheumatoid Arthritis: A Retrospective Analysis of Real-World Data from the St. Gallen and Aarau Cohorts Ruediger B. Müeller, Caroline Hasler, Florian Popp, Journal of Clinical Medicine	2019	48
Real-World Effectiveness of Belimumab in the Treatment of Systemic Lupus Erythematosus: Pooled Analysis of Multi-Country Data from the OBSErve Studies Christopher Collins, Josefina Cortés-Hernández, Mercedes García, Rheumatology and Therapy	2020	47
Effectiveness, tolerability, and safety of subcutaneous methotrexate in early rheumatoid arthritis: A retrospective analysis of real-world data from the St. Gallen cohort Rüdiger Müller, Johannes von Kempis, Sarah R. Haile, Seminars in Arthritis and Rheumatism Rheumatoid DisorderRheumatologySt. Gallen CohortRheumatic DiseasesClinical Epidemiology	2015	45
Rheumatoid arthritis secondary non-responders to TNF can attain an efficacious and safe response by switching to certolizumab pegol: a phase IV, randomised, multicentre, double-blind, 12-week study, followed by a 12-week open-label phase Michael Schiff, Johannes von Kempis, Ronald Goldblum, Annals of the Rheumatic Diseases	2014	45
Clinical outcomes in patients with systemic lupus erythematosus treated with belimumab in clinical practice settings: a retrospective analysis of results from the OBSErve study in Switzerland Johannes von Kempis, Sabine Duetsch, Nicola Reuschling, Swiss Medical Weekly	2019	38
Long-Term Increase of Radiographic Damage and Disability in Patients with RA in Relation to Disease Duration in the Era of Biologics. Results from the SCQM Cohort Katja Heinimann, Johannes von Kempis, Rafael Sauter, Journal of Clinical Medicine	2018	21

Page 1